Tectonic Therapeutic (TECX) Price & Analysis

Compare

550 Followers

TECX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$13.70 - $61.07

Previous CloseN/A

Volume30.18K

Average Volume (3M)202.59K

Market Cap

$480.71M

Enterprise Value$85.73M

Total Cash (Recent Filing)$287.38M

Total Debt (Recent Filing)$1.94M

Price to Earnings (P/E)―

Beta1.33

Next Earnings

Nov 06, 2025

EPS Estimate

-1.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.07

Shares Outstanding18,712,128

10 Day Avg. Volume191,004

30 Day Avg. Volume202,589

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.18

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-52.53

Enterprise Value/Ebitda-1.28

Forecast

1Y Price Target

$83.60

Price Target Upside226.95% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical TrialsTectonic Therapeutic is planning to initiate a Phase 2 trial with TX-45 in pulmonary hypertension associated with interstitial lung disease (PH-ILD) as a potential first-in-class relaxin therapy for this indication.

Financial PositionTectonic's financial position is robust, with $306.2M in cash expected to support operations for several years.

Strategic ExpansionTECX's decision to expand TX45 into another new indication is a strategically positive step that increases optionality.

Bears Say

Clinical Trial UncertaintyStudy results will have perception implications for TECX’s TX45 likelihood of success.

Market SentimentThe short interest in Tectonic Therapeutic stock is relatively high at 17.8% of the float.

Previous Trial OutcomesWe need to learn more about venloraxin’s failure in the Ph2 HFpEF trial and the halting of the Ph2 chronic kidney disease trial.

Tectonic Therapeutic News

Tectonic Therapeutic’s Strategic Expansion and Financial Stability Justify Buy Rating

Leerink Partners analyst David Risinger reiterated a Buy rating on Tectonic Therapeutic yesterday and set a price target...

18d ago

TECX

Tectonic Therapeutic’s Strategic Advancements and Promising Pipeline Drive Buy Rating

In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Tectonic Therapeutic,...

22d ago

TECX

Promising Outlook for Tectonic Therapeutic: Strategic Differentiation and Market Opportunities

Leerink Partners analyst David Risinger has maintained their bullish stance on TECX stock, giving a Buy rating yesterday....

22d ago

TECX

Tectonic Therapeutic Inc. Reports Increased Cash Reserves

Tectonic Therapeutic Inc ( ($TECX) ) has released its Q2 earnings. Here is a breakdown of the information...

22d ago

TECX

Tectonic Therapeutic Reports Q2 Financial Results

The latest announcement is out from Tectonic Therapeutic ( ($TECX) ). On August 7, 2025, Tectonic Therapeutic announced...

22d ago

TECX

Tectonic Therapeutic initiated with a Buy at Truist

Truist initiated coverage of Tectonic Therapeutic (TECX) with a Buy rating and $64 price target Tectonic is advancing...

1M ago

TECX

Closing Bell Movers: Merit Medical Systems gains after Q2 outlook

In the opening hour of the evening session, U.S. equity futures are down again following a post-holiday session...

2M ago

BIIB

MMSI

Tectonic Therapeutic files $400M mixed securities shelf

17:50 EDT Tectonic Therapeutic (TECX) files $400M mixed securities shelf Published first on TheFly – the ultimate source...

2M ago

TECX

Tectonic Therapeutic joins Russell 3000 Index

Tectonic Therapeutic (TECX) announced that it has been added to the broad-market Russell 3000 Index. Tectonic’s addition follows...

2M ago

TECX

Tectonic Therapeutic resumed with an Outperform at Raymond James

Raymond James resumed coverage of Tectonic Therapeutic (TECX) with an Outperform rating and $76 price target as part...

3M ago

TECX

Tectonic Therapeutic Holds 2025 Annual Stockholders Meeting

Tectonic Therapeutic ( ($TECX) ) has provided an update. On June 6, 2025, Tectonic Therapeutic, Inc. held its...

3M ago

TECX

Tectonic Therapeutic initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of Tectonic Therapeutic (TECX) with an Outperform rating and $87 price target Published first...

3M ago

TECX

Tectonic Therapeutic’s TX45: A Promising Solution for Unmet Medical Needs in Pulmonary Hypertension

Cory Jubinville, PhD, an analyst from LifeSci Capital, has initiated a new Buy rating on Tectonic Therapeutic (TECX)....

3M ago

TECX

Tectonic Therapeutic Reports Q1 2025 Financial Results

Tectonic Therapeutic Inc ( ($TECX) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

TECX

TECX FAQ

What was Tectonic Therapeutic’s price range in the past 12 months?

Tectonic Therapeutic lowest stock price was $13.70 and its highest was $61.07 in the past 12 months.

What is Tectonic Therapeutic’s market cap?

Tectonic Therapeutic’s market cap is $480.71M.

When is Tectonic Therapeutic’s upcoming earnings report date?

Tectonic Therapeutic’s upcoming earnings report date is Nov 06, 2025 which is in 68 days.

How were Tectonic Therapeutic’s earnings last quarter?

Tectonic Therapeutic released its earnings results on Aug 07, 2025. The company reported -$1.07 earnings per share for the quarter, missing the consensus estimate of -$0.977 by -$0.093.

Is Tectonic Therapeutic overvalued?

According to Wall Street analysts Tectonic Therapeutic’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tectonic Therapeutic pay dividends?

Tectonic Therapeutic does not currently pay dividends.

What is Tectonic Therapeutic’s EPS estimate?

Tectonic Therapeutic’s EPS estimate is -1.06.

How many shares outstanding does Tectonic Therapeutic have?

Tectonic Therapeutic has 18,712,128 shares outstanding.

What happened to Tectonic Therapeutic’s price movement after its last earnings report?

Tectonic Therapeutic reported an EPS of -$1.07 in its last earnings report, missing expectations of -$0.977. Following the earnings report the stock price went up 1.779%.

Which hedge fund is a major shareholder of Tectonic Therapeutic?

Currently, no hedge funds are holding shares in TECX

Tectonic Therapeutic Stock Smart Score

Neutral

Fundamentals

Return on Equity

-29.32%

Trailing 12-Months

Asset Growth

52.29%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tectonic Therapeutic

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.

Tectonic Therapeutic (TECX) Earnings & Revenues

Historic Earnings Reports

TECX Stock 12 Month Forecast

Average Price Target

$83.60

▲(226.95% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","36":"$36","58":"$58","80":"$80","102":"$102"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":101,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$101.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$83.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$69.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,36,58,80,102],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.73,26.904615384615383,33.07923076923077,39.253846153846155,45.428461538461534,51.60307692307693,57.777692307692305,63.952307692307684,70.12692307692308,76.30153846153846,82.47615384615385,88.65076923076923,94.8253846153846,{"y":101,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.73,25.566153846153846,30.40230769230769,35.238461538461536,40.074615384615385,44.910769230769226,49.74692307692307,54.583076923076916,59.419230769230765,64.25538461538461,69.09153846153845,73.9276923076923,78.76384615384615,{"y":83.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.73,24.443076923076923,28.156153846153845,31.869230769230768,35.582307692307694,39.29538461538462,43.00846153846154,46.72153846153846,50.434615384615384,54.14769230769231,57.860769230769236,61.57384615384615,65.28692307692307,{"y":69,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.9,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.77,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.33,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.14,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.28,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.66,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >